Proton Pump Inhibitor Utilization and Gastrointestinal Health
Summary
Proton pump inhibitors (PPIs) constitute one of the most widely prescribed classes of medication for acid-related disorders, including gastro-oesophageal reflux disease, peptic ulcer disease and prevention of non-steroidal anti-inflammatory drug-induced mucosal injury. By irreversibly inhibiting the H+/K+-ATPase enzyme on gastric parietal cells, PPIs suppress acid secretion and provide rapid symptom relief. In recent decades, the convenience of short-term prescribing has led to extensive long-term and off-label use, raising concerns over unintended effects on gastrointestinal microbiota, mineral absorption and systemic organ systems. Emerging data link extended PPI therapy to risks of respiratory infections, renal impairment, bone fragility and potential neoplasia at the gastric mucosa. Efforts to optimise benefit–risk balance now emphasise personalised prescribing, regular review of ongoing indications and targeted deprescribing when appropriate. Advances in molecular pharmacology and large-scale epidemiological analyses have begun to inform safer strategies for PPI stewardship and patient-centred care.
Research from Nature Portfolio
Recent studies have demonstrated the value of risk-based approaches to PPI prescribing. A large international cohort analysis across two million adults revealed that chronic PPI exposure is associated in a dose-dependent manner with an elevated occurrence of diverse conditions—ranging from ischaemic heart disease and diabetes to chronic kidney disease—and that absolute risks concentrate within higher baseline-risk strata, underscoring the need for individualised decision frameworks. In parallel, a chemoproteomic investigation of rabeprazole has uncovered an alternative activation pathway: zinc-binding centres in non-acidic environments can catalyse prodrug conversion, leading to covalent modification of C4 zinc-cluster proteins. This discovery of pH-independent activation not only broadens understanding of PPI pharmacodynamics but also raises the possibility of off-target interactions beyond the stomach.
Proton Pump Inhibitor Utilization and Gastrointestinal Health publication trend
The graph below shows the total number of articles in proton pump inhibitor utilization and gastrointestinal health across all publications each year (not limited to Nature Index journals).
Technical terms
Proton pump inhibitor (PPI): A class of drugs that irreversibly bind to the gastric H+/K+-ATPase enzyme, suppressing acid secretion from parietal cells.
Risk stratification: The process of classifying patients according to predicted risk of adverse outcomes to inform tailored therapeutic decisions.
Prodrug: An inactive precursor molecule that undergoes enzymatic or chemical conversion within the body to release the active drug.
Hypochlorhydria: A clinical state characterised by reduced gastric acid secretion, which may impact digestion and microbiota composition.
References
- Individualized prevention of proton pump inhibitor related adverse events by risk stratification. Nature Communications (2024).
- Site-specific activation of the proton pump inhibitor rabeprazole by tetrathiolate zinc centres. Nature Chemistry (2025).
- Proton pump inhibitor use: systematic review of global trends and practices. European Journal of Clinical Pharmacology (2023).
- Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis. PLOS ONE (2015).
- Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open (2017).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.